Peter gained his degree in chemistry from the University of Bristol and began his career as a medicinal chemist, focusing on the research and development of novel GLP-1 secretagogues for the treatment of diabetes and obesity. His work led to several patent applications, where he is named as a co-inventor. 

He later transitioned into Regulatory Affairs, joining Mylan (now Viatris), where he managed post-approval CMC changes for various markets, especially Germany, working closely with affiliate offices and quality functions. At Wainwright Associates (now Pharmalex), he expanded his expertise across regulatory strategy, eCTD publishing, GDP, and CMC. 

In 2014, Peter joined EUDRAC  and was promoted over time to Regulatory Affairs Director and member of the UK Management Team. Following EUDRAC’s integration into QbD Group in 2022, he took on his current dual role. 

Peter has worked with clients of all sizes — from start-ups to large multinationals — on regulatory strategy, due diligence, and scientific advice, particularly for orphan and rare disease products. He has successfully supported numerous EU and UK Marketing Authorisation Applications and is highly experienced in lifecycle management, often serving as the primary EMA or MHRA contact for client products. 

In addition, Peter has led many CMC development projects, authored expert reports, and acted as project manager in collaborations with contract manufacturing organisations — several of which resulted in timely and successful commercial product launches.